Suppr超能文献

动脉瘤样骨囊肿变异易位通过与ZNF9、COL1A1、TRAP150和OMD基因启动子交换上调USP6转录。

Aneurysmal bone cyst variant translocations upregulate USP6 transcription by promoter swapping with the ZNF9, COL1A1, TRAP150, and OMD genes.

作者信息

Oliveira Andre M, Perez-Atayde Antonio R, Dal Cin Paola, Gebhardt Mark C, Chen Chang-Jie, Neff James R, Demetri George D, Rosenberg Andrew E, Bridge Julia A, Fletcher Jonathan A

机构信息

Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.

出版信息

Oncogene. 2005 May 12;24(21):3419-26. doi: 10.1038/sj.onc.1208506.

Abstract

Aneurysmal bone cysts (ABC) are locally aggressive bone tumors that often feature chromosome 17p13 rearrangements. One of the ABC 17p13 rearrangements--t(16;17)(q22;p13)--was recently shown to create a CDH11-USP6 fusion in which the USP6/TRE17 oncogene is overexpressed through juxtaposition with the CDH11 promoter. Herein, we characterize four different ABC translocations involving 17p13, and we show that each is associated with a novel USP6 fusion oncogene. Specifically, we demonstrate that t(1;17), t(3;17), t(9;17), and t(17;17) result in USP6 fusions with TRAP150 (thyroid receptor-associated protein 150), ZNF9 (ZiNc Finger 9), Osteomodulin, and COL1A1 (Collagen 1A1), respectively. The oncogenic mechanism in these fusion genes is akin to CDH11-USP6, with the USP6 coding sequences juxtaposed to the promoter regions in each of the four novel translocation partners. The novel fusion partners appear well suited to drive USP6 transcription in the bone/mesenchymal context: osteomodulin is expressed strongly in osteoblastic lineages, and the COL1A1 promoter has an oncogenic role in the mesenchymal cancer dermatofibrosarcoma protuberans. In summary, these studies show that USP6 oncogenic activation results from heterogeneous genomic mechanisms involving USP6 transcriptional upregulation by juxtaposition with ectopic promoters.

摘要

动脉瘤样骨囊肿(ABC)是具有局部侵袭性的骨肿瘤,常伴有17号染色体p13重排。最近发现ABC的一种17p13重排——t(16;17)(q22;p13)——会产生CDH11-USP6融合基因,其中USP6/TRE17癌基因通过与CDH11启动子并列而过度表达。在此,我们对涉及17p13的四种不同ABC易位进行了表征,并表明每种易位都与一种新的USP6融合癌基因相关。具体而言,我们证明t(1;17)、t(3;17)、t(9;17)和t(17;17)分别导致USP6与TRAP150(甲状腺受体相关蛋白150)、ZNF9(锌指9)、骨调节蛋白和COL1A1(胶原蛋白1A1)融合。这些融合基因中的致癌机制类似于CDH11-USP6,USP6编码序列与四个新易位伙伴中每个伙伴的启动子区域并列。新的融合伙伴似乎非常适合在骨/间充质环境中驱动USP6转录:骨调节蛋白在成骨细胞谱系中强烈表达,COL1A1启动子在间质性癌隆突性皮肤纤维肉瘤中具有致癌作用。总之,这些研究表明,USP6致癌激活是由异质性基因组机制导致的,该机制涉及通过与异位启动子并列使USP6转录上调。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验